WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Judge orders man accused of opening fire outside Wrigley Field held without bail
With so many prospects playing well in the minors, Orioles GM has some tricky decisions ahead
Xi leads China in boosting tech self
Active role of overseas Chinese hailed at event
Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
Top leadership hails efforts in flood control
Reims and Rennes drop points in the French league chase for a European place
Search continues in Maine as officer is charged with lying about taking missing person to hospital
Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
Leaders stress environmental cooperation
Lafrenière continuing his breakthrough season as a solid contributor for Rangers in NHL playoffs
Full Text: Remarks by Chinese President Xi Jinping at China